Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

Natsumi Namba; Aya Kawasaki; Ken Ei Sada; Fumio Hirano; Shigeto Kobayashi; Hidehiro Yamada; Hiroshi Furukawa; Kota Shimada; Atsushi Hashimoto; Toshihiro Matsui; Kenji Nagasaka; Takahiko Sugihara; Aika Suzuki; Kunihiro Yamagata; Takayuki Sumida; Shigeto Tohma; Sakae Homma; Shoichi Ozaki; Hiroshi Hashimoto; Hirofumi Makino; Yoshihiro Arimura; Masayoshi Harigai; Naoyuki Tsuchiya

doi:10.1136/annrheumdis-2018-214263

Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

Natsumi Namba, Aya Kawasaki, Ken Ei Sada, Fumio Hirano, Shigeto Kobayashi, Hidehiro Yamada, Hiroshi Furukawa, Kota Shimada, Atsushi Hashimoto, Toshihiro Matsui, Kenji Nagasaka, Takahiko Sugihara, Aika Suzuki, Kunihiro Yamagata, Takayuki Sumida, Shigeto Tohma, Sakae Homma, Shoichi Ozaki, Hiroshi Hashimoto, Hirofumi MakinoYoshihiro Arimura, Masayoshi Harigai, Naoyuki Tsuchiya

Research output: Contribution to journal › Letter › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	1144-1146
Number of pages	3
Journal	Annals of the rheumatic diseases
Volume	78
Issue number	8
DOIs	https://doi.org/10.1136/annrheumdis-2018-214263
Publication status	Published - Aug 1 2019

Keywords

ANCA-associated vasculitis
MUC5B
interstitial lung disease
myeloperoxidase-ANCA
polymorphism

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1136/annrheumdis-2018-214263

Cite this

Namba, N., Kawasaki, A., Sada, K. E., Hirano, F., Kobayashi, S., Yamada, H., Furukawa, H., Shimada, K., Hashimoto, A., Matsui, T., Nagasaka, K., Sugihara, T., Suzuki, A., Yamagata, K., Sumida, T., Tohma, S., Homma, S., Ozaki, S., Hashimoto, H., ... Tsuchiya, N. (2019). Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Annals of the rheumatic diseases, 78(8), 1144-1146. https://doi.org/10.1136/annrheumdis-2018-214263

Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. / Namba, Natsumi; Kawasaki, Aya; Sada, Ken Ei; Hirano, Fumio; Kobayashi, Shigeto; Yamada, Hidehiro; Furukawa, Hiroshi; Shimada, Kota; Hashimoto, Atsushi; Matsui, Toshihiro; Nagasaka, Kenji; Sugihara, Takahiko; Suzuki, Aika; Yamagata, Kunihiro; Sumida, Takayuki; Tohma, Shigeto; Homma, Sakae; Ozaki, Shoichi; Hashimoto, Hiroshi; Makino, Hirofumi; Arimura, Yoshihiro; Harigai, Masayoshi; Tsuchiya, Naoyuki.

In: Annals of the rheumatic diseases, Vol. 78, No. 8, 01.08.2019, p. 1144-1146.

Research output: Contribution to journal › Letter › peer-review

Namba, N, Kawasaki, A, Sada, KE, Hirano, F, Kobayashi, S, Yamada, H, Furukawa, H, Shimada, K, Hashimoto, A, Matsui, T, Nagasaka, K, Sugihara, T, Suzuki, A, Yamagata, K, Sumida, T, Tohma, S, Homma, S, Ozaki, S, Hashimoto, H, Makino, H, Arimura, Y, Harigai, M & Tsuchiya, N 2019, 'Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis', Annals of the rheumatic diseases, vol. 78, no. 8, pp. 1144-1146. https://doi.org/10.1136/annrheumdis-2018-214263

Namba, Natsumi ; Kawasaki, Aya ; Sada, Ken Ei ; Hirano, Fumio ; Kobayashi, Shigeto ; Yamada, Hidehiro ; Furukawa, Hiroshi ; Shimada, Kota ; Hashimoto, Atsushi ; Matsui, Toshihiro ; Nagasaka, Kenji ; Sugihara, Takahiko ; Suzuki, Aika ; Yamagata, Kunihiro ; Sumida, Takayuki ; Tohma, Shigeto ; Homma, Sakae ; Ozaki, Shoichi ; Hashimoto, Hiroshi ; Makino, Hirofumi ; Arimura, Yoshihiro ; Harigai, Masayoshi ; Tsuchiya, Naoyuki. / Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. In: Annals of the rheumatic diseases. 2019 ; Vol. 78, No. 8. pp. 1144-1146.

@article{fc5a965cbf644b218c34d5fc568725e6,

title = "Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis",

keywords = "ANCA-associated vasculitis, MUC5B, interstitial lung disease, myeloperoxidase-ANCA, polymorphism",

author = "Natsumi Namba and Aya Kawasaki and Sada, {Ken Ei} and Fumio Hirano and Shigeto Kobayashi and Hidehiro Yamada and Hiroshi Furukawa and Kota Shimada and Atsushi Hashimoto and Toshihiro Matsui and Kenji Nagasaka and Takahiko Sugihara and Aika Suzuki and Kunihiro Yamagata and Takayuki Sumida and Shigeto Tohma and Sakae Homma and Shoichi Ozaki and Hiroshi Hashimoto and Hirofumi Makino and Yoshihiro Arimura and Masayoshi Harigai and Naoyuki Tsuchiya",

note = "Funding Information: Competing interests FH is employed by The Department of Lifetime Clinical Immunology of Tokyo Medical and Dental University (TMDU), which has received unrestricted research grants from Chugai Pharmaceutical Co, Ltd. Ono Pharmaceuticals; Mitsubishi Tanabe Pharma Co. UCB Japan; CSL Behring; Towa Pharmaceutical Co, Ltd. Abbvie Japan Co, Ltd. Japan Blood Products Organization; Ayumi Pharmaceutical Co; and Nippon Kayaku Co, Ltd, with which TMDU currently pays the salary of FH. FH has also received speaking fees from Ono Pharmaceuticals, Astellas Pharma Inc. Sumitomo Dainippon Pharma and Chugai Pharmaceutical Co, Ltd. KS has received lecture fee from Chugai. HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co, Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co, Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co, Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co, Ltd. Pfizer Japan Inc, and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd, and Ayumi Pharmaceutical Corporation. ST was supported by research grants from Abbott Japan Co, Ltd, Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd, Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc. Pfizer Japan Inc, Takeda Pharmaceutical Company Limited and Teijin Pharma Limited. TSug has received honoraria from Chugai Pharmaceutical Co, Ltd. Takeda Pharmaceutical Co. Ltd, Mitsubishi-Tanabe Pharma Co, Astellas Pharma Inc, Bristol Myers Squibb K.K. Pfizer Japan Inc, UCB Japan Co. Ltd, and Abbvie Japan Co, Ltd, and has received research grant support from Takeda Pharmaceutical Co, Ltd, Astellas Pharma Inc, and Teijin Pharma Ltd. AH has received research funding from Chugai Pharmaceutical Co, Ltd. HM is a consultant for AbbVie and Teijin, receives speaker honoraria from Boehringer-Ingelheim. MH has received research grants and/or honoraria from Abbott Japan Co, Ltd. Astellas Pharma Inc; Bristol-Myers Squibb K.K. Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd. Janssen Pharmaceutical K.K. Mitsubishi Tanabe Pharma Co; Santen Pharmaceutical Co; Ltd. Takeda Pharmaceutical Co, Ltd. Teijin Pharma, Ltd. and Pfizer Japan Inc. NT has received 2015 Japan College of Rheumatology Award from Japan College of Rheumatology and 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research fundings, and speaker{\textquoteright}s honoraria from Ayumi Pharmaceutical Corporation. Funding Information: Funding This study was supported by the grants from the Japan Agency for Medical Research and Development {"}The Study Group for Strategic Exploration of Drug Seeds for ANCA Associated Vasculitis and Construction of Clinical Evidence (grant number 17ek0109104h0003)”, ”The Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline (grant number 17ek0109121h0003)” and “Multitiered study to address clinical questions for management of intractable vasculitides (grant number 18ek0109360h001){"}, and an award grant from Japan College of Rheumatology.",

year = "2019",

month = aug,

day = "1",

doi = "10.1136/annrheumdis-2018-214263",

language = "English",

volume = "78",

pages = "1144--1146",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "8",

}

TY - JOUR

T1 - Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

AU - Namba, Natsumi

AU - Kawasaki, Aya

AU - Sada, Ken Ei

AU - Hirano, Fumio

AU - Kobayashi, Shigeto

AU - Yamada, Hidehiro

AU - Furukawa, Hiroshi

AU - Shimada, Kota

AU - Hashimoto, Atsushi

AU - Matsui, Toshihiro

AU - Nagasaka, Kenji

AU - Sugihara, Takahiko

AU - Suzuki, Aika

AU - Yamagata, Kunihiro

AU - Sumida, Takayuki

AU - Tohma, Shigeto

AU - Homma, Sakae

AU - Ozaki, Shoichi

AU - Hashimoto, Hiroshi

AU - Makino, Hirofumi

AU - Arimura, Yoshihiro

AU - Harigai, Masayoshi

AU - Tsuchiya, Naoyuki

N1 - Funding Information: Competing interests FH is employed by The Department of Lifetime Clinical Immunology of Tokyo Medical and Dental University (TMDU), which has received unrestricted research grants from Chugai Pharmaceutical Co, Ltd. Ono Pharmaceuticals; Mitsubishi Tanabe Pharma Co. UCB Japan; CSL Behring; Towa Pharmaceutical Co, Ltd. Abbvie Japan Co, Ltd. Japan Blood Products Organization; Ayumi Pharmaceutical Co; and Nippon Kayaku Co, Ltd, with which TMDU currently pays the salary of FH. FH has also received speaking fees from Ono Pharmaceuticals, Astellas Pharma Inc. Sumitomo Dainippon Pharma and Chugai Pharmaceutical Co, Ltd. KS has received lecture fee from Chugai. HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co, Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co, Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co, Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co, Ltd. Pfizer Japan Inc, and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd, and Ayumi Pharmaceutical Corporation. ST was supported by research grants from Abbott Japan Co, Ltd, Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd, Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc. Pfizer Japan Inc, Takeda Pharmaceutical Company Limited and Teijin Pharma Limited. TSug has received honoraria from Chugai Pharmaceutical Co, Ltd. Takeda Pharmaceutical Co. Ltd, Mitsubishi-Tanabe Pharma Co, Astellas Pharma Inc, Bristol Myers Squibb K.K. Pfizer Japan Inc, UCB Japan Co. Ltd, and Abbvie Japan Co, Ltd, and has received research grant support from Takeda Pharmaceutical Co, Ltd, Astellas Pharma Inc, and Teijin Pharma Ltd. AH has received research funding from Chugai Pharmaceutical Co, Ltd. HM is a consultant for AbbVie and Teijin, receives speaker honoraria from Boehringer-Ingelheim. MH has received research grants and/or honoraria from Abbott Japan Co, Ltd. Astellas Pharma Inc; Bristol-Myers Squibb K.K. Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd. Janssen Pharmaceutical K.K. Mitsubishi Tanabe Pharma Co; Santen Pharmaceutical Co; Ltd. Takeda Pharmaceutical Co, Ltd. Teijin Pharma, Ltd. and Pfizer Japan Inc. NT has received 2015 Japan College of Rheumatology Award from Japan College of Rheumatology and 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research fundings, and speaker’s honoraria from Ayumi Pharmaceutical Corporation. Funding Information: Funding This study was supported by the grants from the Japan Agency for Medical Research and Development "The Study Group for Strategic Exploration of Drug Seeds for ANCA Associated Vasculitis and Construction of Clinical Evidence (grant number 17ek0109104h0003)”, ”The Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline (grant number 17ek0109121h0003)” and “Multitiered study to address clinical questions for management of intractable vasculitides (grant number 18ek0109360h001)", and an award grant from Japan College of Rheumatology.

PY - 2019/8/1

Y1 - 2019/8/1

KW - ANCA-associated vasculitis

KW - MUC5B

KW - interstitial lung disease

KW - myeloperoxidase-ANCA

KW - polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85061621500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061621500&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2018-214263

DO - 10.1136/annrheumdis-2018-214263

M3 - Letter

C2 - 30765393

AN - SCOPUS:85061621500

VL - 78

SP - 1144

EP - 1146

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 8

ER -

Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this